# Polyneuron Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/polyneuron-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Basel, Switzerland
- Website: www.polyneuron.com
- Total disclosed funding: $41M
- Latest round: Series A (Aug 28, 2020)
- Investors on record: 6

## About

Polyneuron Pharmaceuticals AG, based in Switzerland, develops innovative therapeutic solutions targeting antibody-mediated autoimmune diseases, leveraging its proprietary Antibody-Catch™ technology platform.Founded in 2014 and headquartered in Basel, Switzerland, Polyneuron Pharmaceuticals AG specializes in developing treatments for autoimmune diseases. The company focuses on therapeutic candidates that address conditions like anti-MAG neuropathy and Guillain-Barré Syndrome. Polyneuron has successfully secured CHF 10.820 mn in funding through five deals, with the latest funding round being a Grant of CHF 1.200 mn from Innosuisse - Swiss Innovation Agency, completed on April 14, 2021.Polyneuron Pharmaceuticals is focused on developing innovative therapeutic solutions for antibody-mediated autoimmune diseases using its proprietary Antibody-Catch™ technology platform. Its core product offerings include PN-1007 (PPSGG), which targets IgM autoantibodies associated with anti-MAG neuropathy, and PN-1018, designed for Guillain-Barré Syndrome (GBS) and Multifocal Motor Neuropathy (MMN). These injectable glycopolymers act as decoys to selectively bind and eliminate pathogenic autoantibodies while preserving the normal immune response, thereby addressing severe autoimmune conditions that currently lack effective treatments. Polyneuron’s pipeline also includes PN-032 and PN-056, aimed at the selective depletion of isoagglutinin antibodies for ABO-incompatible organ and stem cell transplantation. The company's products primarily cater to medical professionals, healthcare institutions, and patients in multiple geographies, particularly in Europe and North America, where there is a significant unmet medical need for targeted autoimmune therapies.Polyneuron Pharmaceuticals operates within the biopharmaceutical industry, primarily generating revenue through the development and commercialization of its therapeutic candidates. The company has raised approximately CHF 36.5 million to date, which supports its ongoing research and clinical trials. Business transactions typically involve partnerships with healthcare providers, biopharma companies, and research institutions, focusing on B2B collaborations for clinical development and distribution of its products. The company’s flagship offerings, such as PN-1007 and PN-1018, are positioned to enter various stages of clinical trials and subsequent market release, with pricing determined through agreements with healthcare systems and potential reimbursement strategies. These arrangements aim to ensure accessibility for patients while supporting the sustainability of Polyneuron’s innovative drug development efforts.In April 2021, Polyneuron Pharmaceuticals AG received CHF 1.2 million of grant funding from Innosuisse - Swiss Innovation Agency. The funding will be utilized to advance the development of novel treatments to support ABO-incompatible (ABOi) transplantation patient outcomes. The company is actively working on launching new products and expanding its presence in European and North American markets to address unmet medical needs in autoimmune therapeutics.

## Funding rounds

- Series A, Aug 28, 2020, $12M — HBM Partners
- Series A, Mar 28, 2019, $23M — New Enterprise Associates, Sofinnova Partners
- Seed, May 11, 2018, $3.1M — Zürcher Kantonalbank, EVA
- Seed, May 11, 2016, $3.1M — EVA, ZKB Pharma Vision Fund

## Investors

- EVA (https://capitalatlas.ai/funds/eva) — Seed
- ZKB Pharma Vision Fund — Seed
- Zürcher Kantonalbank — Seed
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A
- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series A
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series A